title: Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor.
abstract: BACKGROUND
  Although hepatitis C virus (HCV) transmission through tissue transplantation has been rarely reported, a donor with undetected viremia may infect several recipients. A patient developed acute hepatitis C shortly after tissue transplantation. Ninety-one tissues or organs had been recovered from the donor.
  
  
  OBJECTIVE
  To determine whether the donor was the source of infection and the extent of transmission to other organ and tissue recipients.
  
  
  METHODS
  Descriptive epidemiologic study; serum testing for HCV infection.
  
  
  METHODS
  Recipients were located in 16 states and 2 other countries.
  
  
  METHODS
  Donor and graft recipients.
  
  
  METHODS
  Hepatitis C virus infection was defined as the presence of anti-HCV or HCV RNA. The authors determined the genetic relatedness of viral isolates from the donor and recipients by genotype comparison and quasi-species analysis.
  
  
  RESULTS
  The donor was anti-HCV-negative but was HCV RNA-positive (genotype 1a). Forty persons received transplants during 22 months. Five persons were HCV-infected before transplantation or had a genotype other than 1a, and 5 persons had no post-transplantation serum specimens available. Of the remaining 30 recipients, HCV infection occurred in 8 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and 3 of 3 tendon with bone recipients. These 8 recipients had viral isolates genetically related to those of the donor. No cases occurred in recipients of skin (n = 2), cornea (n = 1), or irradiated bone (n = 16).
  
  
  CONCLUSIONS
  Post-transplantation serum specimens were unavailable for 5 recipients.
  
  
  CONCLUSIONS
  An anti-HCV-negative donor was the source of HCV infection for 8 recipients of organs or tissues. Although HCV transmission from anti-HCV-negative donors is probably uncommon, changes in donor screening to include routine testing for HCV RNA merit further consideration to improve the safety of transplantation.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. barna.tugwell@cdha.nshealth.ca
authors.forename: Barna D
authors.initials: BD
authors.lastname: Tugwell
authors.forename: Priti R
authors.initials: PR
authors.lastname: Patel
authors.forename: Ian T
authors.initials: IT
authors.lastname: Williams
authors.forename: Katrina
authors.initials: K
authors.lastname: Hedberg
authors.forename: Feng
authors.initials: F
authors.lastname: Chai
authors.forename: Omana V
authors.initials: OV
authors.lastname: Nainan
authors.forename: Ann R
authors.initials: AR
authors.lastname: Thomas
authors.forename: Judith E
authors.initials: JE
authors.lastname: Woll
authors.forename: Beth P
authors.initials: BP
authors.lastname: Bell
authors.forename: Paul R
authors.initials: PR
authors.lastname: Cieslak
mesh_terms: D005260:Female; D016174:Hepacivirus / Q000276:immunology* / Q000302:isolation & purification; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000635:transmission* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000592:standards*; D012367:RNA, Viral / Q000097:blood; D014019:Tissue Donors; D016378:Tissue Transplantation / Q000592:standards*; D009927:Tissue and Organ Procurement / Q000592:standards; D014766:Viremia / Q000175:diagnosis
chemical_list: D006508:Hepatitis Antibodies; D012367:RNA, Viral